Realfiction (REALFI) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
5 Jun, 2025Executive summary
Revenue nearly doubled year-over-year to TSEK 18,619, driven by a major DPT proof-of-concept sale and strong mixed reality display sales.
Signed first significant license and collaboration agreement with Goworld, enabling mass manufacturing of DPT products.
Positive cash flow in Q4-2024 extended liquidity outlook into August 2025.
Commercial traction established with monetization of technology and expanded industry partnerships.
Financial highlights
Q4-2024 revenue: TSEK 4,573 (up 64% year-over-year); full year revenue: TSEK 18,619 (up 88%).
Q4-2024 gross profit: TSEK 3,001; gross margin: 65.6% (down from 69.4%); full year gross margin: 73.4% (up from 65.8%).
Result after financial items: TSEK -5,827 in Q4-2024; TSEK -22,798 for the year (loss widened year-over-year).
Q4-2024 cash flow from operations: TSEK 6,034; full year: TSEK -9,551.
Equity at year-end: TSEK 51,790 (down from TSEK 67,471).
Outlook and guidance
Sufficient liquidity to sustain operations into August 2025, with ongoing evaluation of strategic and financial alternatives.
Focus for 2025 is on converting commercial traction into scalable, revenue-generating partnerships and licensing agreements.
Board confident in ability to secure additional funding to support operational and strategic plans.
Latest events from Realfiction
- Sharp revenue drop in Q3 as DPT sales paused; capital raised to support DPT commercialization.REALFI
Q3 202527 Nov 2025 - SEK 50 million rights issue supports commercialization of advanced glasses-free 3D display tech.REALFI
Status Update23 Nov 2025 - DPT commercialization advances with improved margins and new funding, despite lower revenue.REALFI
Q2 202528 Jul 2025 - Q3-2024 saw record DPT-driven revenue growth and strong gross margins, with liquidity secured.REALFI
Q3 202413 Jun 2025 - Q2-2024 saw strong revenue growth and DPT licensing talks nearing a breakthrough.REALFI
Q2 202413 Jun 2025 - DPT commercialization accelerates with new funding and industry milestones despite lower revenue.REALFI
Q1 20256 Jun 2025